{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:56:03Z","timestamp":1775044563828,"version":"3.50.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals U.S.A., Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/17474086.2026.2619440","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:25:14Z","timestamp":1769012714000},"page":"447-456","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility and outcomes of switching factor VIII therapies: post-hoc analysis of patients transitioning from older plasma-derived and first-generation recombinant factor VIII to newer third-generation recombinant factor VIII replacement therapies within the Takeda factor VIII portfolio"],"prefix":"10.1080","volume":"19","author":[{"given":"Alicia","family":"Cerretani","sequence":"first","affiliation":[{"name":"Takeda Pharmaceuticals America, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Robinson","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A. Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Shtaynberger","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas, Inc","place":["Cambridge, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Caicedo","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Montcrieff","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals U.S.A., Inc","place":["Lexington, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6418","authenticated-orcid":false,"given":"Leonard A","family":"Valentino","sequence":"additional","affiliation":[{"name":"Rush University Medical Center","place":["Chicago, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1381232"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-1208"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.2450\/2019.0211-19"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14046"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1803550"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30054-7"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1042\/ba20010082"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2019.08.010"},{"key":"e_1_3_7_11_1","unstructured":"US Food and Drug Administration [Internet]. HEMOFIL M [antihemophilic factor (human) method M monoclonal purified] US prescribing information. 2023 [cited 2024 Dec 5]. Available from: https:\/\/content.takeda.com\/?contenttype=PI&product=GEN&language=ENG&country=USA&documentnumber=1"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196609012750904"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1993.33593255605.x"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648373"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000217165"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255443"},{"key":"e_1_3_7_17_1","unstructured":"US Food and Drug Administration [Internet]. RECOMBINATE [antihemophilic factor (recombinant)] US prescribing information. 2023 [cited 2024 Dec 5]. Available from: https:\/\/www.shirecontent.com\/PI\/PDFs\/RECOMBINATE_USA_ENG.pdf"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656030"},{"key":"e_1_3_7_19_1","unstructured":"US Food and Drug Administration [Internet]. ADVATE [Antihemophilic factor (recombinant)] US prescribing information. 2023 [cited 2024 Dec 5]. Available from: https:\/\/www.shirecontent.com\/PI\/PDFs\/ADVATE_USA_ENG.pdf"},{"key":"e_1_3_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00932.x"},{"key":"e_1_3_7_21_1","unstructured":"US Food and Drug Administration [Internet]. ELOCATE [Antihemophilic factor (recombinant) fc fusion protein] US prescribing information. 2023 [cited 2024 Dec 16]. Available from: https:\/\/www.fda.gov\/media\/88746\/download?attachment"},{"key":"e_1_3_7_22_1","unstructured":"US Food and Drug Administration [Internet]. ADYNOVATE (antihemophilic factor recombinant PEGylated) US prescribing information. 2023 [cited 2024 Dec 5]. Available from: https:\/\/www.fda.gov\/media\/94470\/download"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-630897"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13119"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12480"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12724"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902729392"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02332.x"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14052"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2247160"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011780"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2025.102931"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2353761"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.17225\/jhp00178"},{"key":"e_1_3_7_35_1","unstructured":"National Bleeding Disorders Foundation [Internet]. Bayer announces discontinuation of Kogenate\u00ae FS. 2022 [cited 2025 Jan 10]. Available from: https:\/\/www.bleeding.org\/news\/bayer-announces-discontinuation-of-kogenater-fs"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S92520"},{"key":"e_1_3_7_37_1","unstructured":"World Federation of Hemophilia (WFH) [Internet]. Takeda to discontinue HEMOFIL M and RECOMBINATE hemophilia drugs. 2025 [cited 2025 Jul 9]. Available from: https:\/\/wfh.org\/article\/takeda-to-discontinue-hemofil-m-and-recombinate-hemophilia-drugs\/"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03032.x"},{"key":"e_1_3_7_39_1","unstructured":"Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry. US Department of Health and Human Services. 2017 [cited 2025 Sep 10]. Available from: https:\/\/www.fda.gov\/files\/drugs\/published\/Multiple-Endpoints-in-Clinical-Trials-Guidance-for-Industry.pdf"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000581"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2015.1092033"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100890"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830310108"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S103796"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2026.2619440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:39:12Z","timestamp":1775039952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2026.2619440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/17474086.2026.2619440"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2026.2619440","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-04-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}